Obesity/Overweight – Current Treatment – Detailed, Expanded Analysis (US): Treatment Algorithms: Claims Data Analysis

Obesity is a significant public health concern in the United States. The body of evidence highlighting the physical and economic impact of obesity on society is growing steadily. The most frequently used first-line therapy remains generic phentermine, a drug that has been on the U.S. market for decades. However, since 2012, several novel branded drugs have entered the market with varying degrees of commercial success. Approved agents include Novo Nordisk’s Wegovy (semaglutide) and Saxenda (liraglutide), Vivus’s Qsymia (phentermine / topiramate), and Currax Pharmaceuticals’ Contrave (naltrexone / bupropion). This report provides important insights into how prescription weight-loss agents are used in the management of obesity and how practices are evolving.

QUESTIONS ANSWERED

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed obese / overweight patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed obese patients?
  • How has Saxenda been integrated into the treatment algorithm, and what is its source of business?
  • What percentage of obese / overweight patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of obese / overweight patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Markets covered: United States.

Key companies: Novo Nordisk, Vivus, Currax Pharmaceuticals.

Key drugs: Saxenda, Qsymia, Contrave, Xenical, phentermine.

SOLUTION ENHANCEMENT

The Treatment Algorithms dashboard is an interactive supplement to our PowerPoint-based claims data analysis reports and retains the full set of analyses included in the reports (i.e., newly diagnosed patients, recently treated patients, persistency, and compliance). The dashboard allows for easier navigation of data visualizations and provides more detailed analyses examining the flow of treatment regimens in newly diagnosed and recently treated patients.

Table of contents

  • Obesity/Overweight - Current Treatment - Detailed, Expanded Analysis (US): Treatment Algorithms: Claims Data Analysis
    • Treatment Algorithms CDA Obesity US May 2022
    • Treatment Algorithms CDA Obesity US 2022 Dashboard

launch Related Market Assessment Reports